A rapid and accurate high speed liquid chromatographic method has been developed for the determination of cephalexin in human plasma and urine. The method involves micropore filtration of urine specimens and methanol extraction of plasma samples followed by HSLC separation on a bonded reverse phase column utilizing a mobile phase of methanolwater containing acetic acid. The quantitativity of UV response at 254 nm covered a wide range of cephalexin concentrations down to 0.5 ,ug/ml, and no metabolite peaks were detected. The time courses of plasma level and urinary excretion were determined until 6 hours after oral administration of cephalexin capsules to healthy volunteers. The pharmacokinetic parameters were estimated using a two compartment open model.
(1,800 p.s.i.) and 0.9mI/min (1,100 p.s.i.) for urine and plasma samples, respectively.
Reagents and Materials The mobile phase was prepared by microfiltration (0.45 ,um) and degassing of a mixture of distilled water and methanol. Acetic acid of analytical grade was used as supplied. The monohydrate form of cephalexin (945 pg/mg as potency) used as standard and cephalexin capsule (Keflex® 250 mg as potency) received by volunteers were provided by Shionogi Seiyaku Co. (Osaka, Japan). The potency of the standard cephalexin was regarded as chemical purity, because no impurity peaks were detected on a chromatogram and any substance undetected at 254 nm, if present, could have no potency. Hence the results given below are those corrected to this purity factor (0.945).
Administration and Sampling
The cephalexin capsules were orally administered to three healthy male volunteers (each 500 nag as potency) who were 28 -37 years of age and 67 -79 kg of body weight. The volunteers were fasted for 12 hours before receiving the capsules. Urine and blood samples were taken just before and after the administration according to the planned time schedule (see Table 1 ). After measuring the volume of urine, a 1-to 2-ml aliquot was filtered through 0.45 pm pore size triacetylcellulose membrane (Fuji Photo Film, Tokyo, Japan) and kept frozen until analysis. Venous blood samples drawn into 2 ml heparinized syringe were immediately transferred to a heavy duty glass tube and centrifuged at 3,600 r.p.m. for 10 minutes to separate the plasma layer. To 0.5 ml of the plasma was added 0.5ml methanol, and the mixture was shaken vigorously for 5 minutes and centrifuged at 3,600 r.p.m. for 10 minutes. The supernate was filtered through the 0.45 um filter and exactly 10'40 pl of the filtrate was used for injection. The volume injected was based on a rough estimation of plasma concentration.
Calibration Graph Calibration graphs were prepared for the determinations of plasma and urine concentrations, respectively. With urine, known amounts of standard cephalexin were dissolved in the control urine to make nine different concentrations between 50 pg/ml and 5 mg/ml. The peak heights were plotted against the concentration ranging from 50 pg/ml to I mg/ml and 500 pg/ml to 5 mg/ml. The linear regression analysis of the plots in the two regions gave the same calibration equation with correlation coefficient 0.9997 and standard deviation 0.06. The control plasma was spiked with standard cephalexin to six different levels between 0.5 pg/ml and 20 pg/ml. After the spiked plasma had been equilibrated by shaking for 10 minutes, a 0.5 ml portion was treated in the same manner as described above. The relationship between peak height and concentration showed good linearity through the origin which also agreed with the calibration graph for the urine samples. Therefore, the calibration graph is common to both plasma and urine samples.
Results and Discussion
It is known that cephalexin is stable in acidic media and its degradation is independent of pH even in strong acidic solution."' The stability of cephalexin in the media used in this study (pH value of mobile phase 3.0-3.1 and urine 5.5-6.5) was examined prior to in vivo experiment. No peaks due to degradation products were found on the chromatograms of ordinary urine and plasma solutions of standard cephalexin, and the intensity of UV response for a given amount of the standard cephalexin was reproducible, when the solutions were stored frozen or even kept at room temperature overnight. As shown in Figs. 1 and 2, separation of the cephalexin peak from background peaks of control plasma and urine was almost complete within the concentration range to be determined. A minor interfering peak was observed on a chromatogram of plasma concentration below 0.2 /1g/ml which, therefore, was the limit of accurate determination. The limit of detection, however, could be as low as 0.1 pg/ml at maximum sensitivity (AUFS 0.005) with 40 pl injection of plasma sample. The increasing water content in the mobile phase produced more increase in the retention time of cephalexin than in those of urinary background peaks. Thus, the water content and flow rate of the mobile phase were adjusted to give complete separation in as short a retention time (16 minutes) as possible.
Since the plasma background peaks, as seen in Fig. 1 , had more scattered retention times than the urinary ones, the water content and flow rate were chosen so that the cephalexin peak had the retention time in between those of two minor background peaks. The difference in the retention times and intensities of background peaks due to individual volunteers did not interfere with the separation of the cephalexin peak, and no peaks were assignable to metabolites. The calibration graph obtained from aqueous solutions of standard cephalexin was found to have the same slope as that from plasma solution. The change in the equilibration time from 10 to 90 minutes in preparing the spiked plasma and the change in the volume of methanol added to plasma from 0.5 to 1.5 ml did not affect the recovery of cephalexin.
Therefore, the present method quantitates the total amount of cephalexin bound and unbound to plasma protein with almost 100% recovery.
One of the advantages of the present method is a simple pretreatment of urine and plasma samples. The ultrafiltration using the membrane-filter can remove the visible particles from urine and macromolecules of plasma protein as well. The filtrate, however, may partly coagulate when introduced into a flow of mobile phase, which may cause a column-filter to be plugged and the packing materials to be stained. Repeated injections of urine and plasma samples actually gave rise to a slight increase in inlet pressure of the mobile phase. Therefore, the column was eluted overnight with large volume of distilled water and methanol after every fifty injections or so, and the column-filter was also cleaned in an ultra-sonic bath. The column efficiency (HETP 0.3 mm for cephalexin) was thus conserved. Table I shows the results for the urinary excretion of cephalexin for each of three subjects and Time (hrs.) at 6.5 hours where the excretion is almost completed. It has been reported that, on average, over 90% of the dose was excreted in human urine in 6 hours after oral administration of cephalexin.'`3j
The investigation of the individual data, however, reveals that microbioassay often gave the urinary recovery considerably exceeding 100%, probably owing to the error in the assay method. The present method, we believe, offers more reliable results than microbioassay, although the general profile of excretion is similar to those earlier reported.
The plasma data obtained are shown in Table 2 where the concentration are given in Itg/ml for each of the volunteers and their mean values along with standard deviations. Fig. 5 illustrates the average plasma level-time curve where the time interval was 30 minutes for the first 3 hours and 1 hour thereafter, that is, the blood samples and urine specimens were taken alternatively every 15 minutes for the first 3.25 hours and 30 minutes for the subsequent 3 hours. It is found that the peak plasma Table 2 . Plasma concentration (aug/ml) of cephalexin following single oral administration of two 250 mgcapsules (500 mg) to healthy volunteers. level of 21.29 ,ug/ml at 1 hour is followed by the monotonic decrease to 0.41 hg/ml at 6 hours after administration. Taking the urinary excretion data into account, these results nuggets that the accumulation of cephalexin in the human body is negligible and the dosing interval of 6 hours which is usually employed clinically may cause a problem in the light of therapeutic effect. The uncorrected renal clearance was estimated as a slope of urinary excretion rate-plasma concentration plots,"" since the plasma samples were taken, as mentioned above, at the midpoint of the urinary collection interval. 
